managing progression in egfr-mutant nsclc patients: potential impact of 2nd and 3rd generation tkis?
Published 8 years ago • 278 plays • Length 19:53Download video MP4
Download video MP3
Similar videos
-
2:36
second- and third-generation tkis in egfr-mutated nsclc
-
20:35
tki-resistant egfr-mutant nsclc
-
21:35
long term management of egfr-mutant nsclc -tsao
-
21:41
beyond erlotinib: are second generation egfr inhibitors better or simply newer?
-
20:31
egfr tkis, their congeners and partners: can we improve outcome in "unselected" patients?
-
20:24
targeted treatment with egfr tkis: front line options
-
20:18
understanding, preventing, and delaying egfr resistance in the era of osimertinib
-
21:09
mechanisms of resistance to egfr tki and new treatment strategies
-
6:02
egfr mutation and cancer
-
5:32
introduction to egfr inhibitors
-
4:44
mechanisms of tki resistance
-
2:20
osimertinib in advanced non–small-cell lung cancer
-
18:06
egfr inhibitors in mutation ( ) patients: current therapeutic strategies in the frontline setting
-
20:27
managing egfr-resistant disease: t790 and beyond
-
13:06
managing t790-negative egfr-mutated nsclc
-
17:27
how, when, and where to utilize erlotinib, afatinib, and gefitinib in egfr positive nsclc
-
23:10
egfr mutation positive tumors: treatment strategies in front line and at relapse
-
33:23
improving survival and managing costs in nsclc: the role of clinical care pathways
-
14:30
adjuvant therapy for egfr mutant nsclc
-
20:07
acquired egfr resistance: what are the current therapeutic strategies?
-
1:48
acquired resistance to third-generation egfr tkis in nsclc
-
0:49
exploring advantages to third-generation tkis in lung cancer